Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21

Trial Status

Recruiting1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT07288034Phase 2Recruiting
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
PrincipalinvestigatorStart date: 2026-05-01

Research Network

Collaboration Network

4 collaborators·3 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Ravi Salgia, MD

City of Hope Medical Center

Moderately Similar
4 trials

Shared therapeutic areas:

Stage IV Lung Cancer AJCC v8Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8

Worked with same sponsors:

City of Hope Medical CenterNational Cancer Institute (NCI)
Collaborated on 1 trial
Similarity Score34%

Arya Amini

City of Hope Medical Center

Moderately Similar
7 trials

Shared therapeutic areas:

Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8

Worked with same sponsors:

City of Hope Medical CenterNational Cancer Institute (NCI)
Similarity Score30%

Sriram Yennu

M.D. Anderson Cancer Center

Moderately Similar
12 trials

Shared therapeutic areas:

Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score30%

Kathrin Milbury

M.D. Anderson Cancer Center

Moderately Similar
7 trials

Shared therapeutic areas:

Stage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score30%

Anurag K Singh

Roswell Park Cancer Institute

Moderately Similar
8 trials

Shared therapeutic areas:

Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score30%

Yasir Y Elamin, MD

M.D. Anderson Cancer Center

Moderately Similar
4 trials

Shared therapeutic areas:

Stage IV Lung Cancer AJCC v8Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score30%

Jorge J Nieva, MD

University of Southern California

Moderately Similar
4 trials

Shared therapeutic areas:

Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score30%

David S Hong

M.D. Anderson Cancer Center

Moderately Similar
5 trials

Shared therapeutic areas:

Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score30%

Roberto F Casal

M.D. Anderson Cancer Center

Related
4 trials

Shared therapeutic areas:

Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score20%

Rahul Aggarwal, MD

University of California, San Francisco

Related
22 trials

Shared therapeutic areas:

Stage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score20%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT07288034Phase 2PrincipalInvestigator

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
Recruiting

All 1 trials loaded